Advertisement

Topics

Latest "Dorian Regulatory Affairs" News Stories

10:43 EDT 18th October 2017 | BioPortfolio

Here are the most relevant search results for "Dorian Regulatory Affairs" found in our extensive news archives from over 250 global news sources.

More Information about Dorian Regulatory Affairs on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Dorian Regulatory Affairs for you to read. Along with our medical data and news we also list Dorian Regulatory Affairs Clinical Trials, which are updated daily. BioPortfolio also has a large database of Dorian Regulatory Affairs Companies for you to search.

Showing "Dorian Regulatory Affairs" News Articles 1–25 of 5,300+

Wednesday 18th October 2017

Adobe Sign Certified Compliant with SAFE-BioPharma Standard

Adobe Sign, the leading e-signature solution that allows anyone to sign and send documents, is now certified compliant with the global SAFE-BioPharma® digital signature standard. Major biopharmaceutical companies that are members of SAFE-BioPharma Association rely on products and services compliant with the standard for critical functions such as applying...


STERIS to Announce Fiscal 2018 Second Quarter Financial Results on November 1, 2017

LEICESTER, U.K.  - October 18, 2017- STERIS plc (NYSE: STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2018 second quarter financial results at 10:00 a.m. Eastern Time on Wednesday, November 1, 2017.  The conference call can be heard live over the Internet at www.steris-ir.com or via phone by dialing 1- ...

Facet Life Sciences Reaches Out to Small Biopharmaceutical Teams

Facet Seeks to Help Small Teams Prepare for Their First IND Wayne, PA (PRWEB) October 18, 2017 Facet Life Sciences, a leading provider of development solutions (software and services) for small and rapidly growing life sciences teams, today announced their participation in two global events. The Facet team will conduct a webinar on Thursday, 19 October 2017 at 11:00 am Eastern titled, Your Compan...


Eccovia Solutions Announces Community Care Coordination Platform Now Hosted in Microsoft Azure Government

Eccovia Solutions announced today that they have strategically expanded their relationship with Microsoft by hosting their leading ClientTrack Platform on the Microsoft Azure Government cloud platform. All of Eccovia Solutions’ more than 1,300 clients are now hosted in this government-only instance of Azure, reaping the benefits of its comprehensive comp...

FluGen Awarded $14.4 million by the Department of Defense to Test Universal Flu Vaccine Against Mismatched Strains

FluGen Inc., announced today that it has been awarded a grant of $14.4 million through the DOD’s Congressionally Directed Medical Research Programs Peer Reviewed Medical Research Program’s (PRMRP) mechanism to conduct clinical challenge-studies against mismatched influenza strains with its lead universal flu vaccine, RedeeFlu™. Under the thr...

Stepping up to the European plate — RAPS launches European Council

The Regulatory Affairs Professionals Society (RAPS) is launching its first European Council (REC) to support its expansion and to increase its presence within the region.

Freenome Announces Formation of Scientific Advisory Board

Inaugural Members Include Leading Experts in Genomics and Machine Learning Freenome, the health technology company creating tools that empower people to prevent, diagnose, and treat their diseases, today announced the formation of its Scientific Advisory Board (SAB) comprised of leading experts in genomics and machine learning. The SAB will serve as ...

Revance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis

- Company expects to report topline eight-week results at the end of the year - Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced it has completed enrollment of patients in the Company’s Phase 2 program investigating the use o...

Medsphere Systems and Stockell Healthcare Sign Merger Agreement

Union of affordable EHR and comprehensive RCM providers yields most complete healthcare IT system available via subscription service payment model Medsphere Systems Corporation and

Biogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive Approach

New data from more than 80 oral and poster presentations, including research on potential predictive and digital biomarkers Updates on real-world data generation initiatives, including MS PATHS, which leverages technology in routine care to produce real-time data, and the Big MS Data Network, intended to provide pooled registry ...

Visterra Announces Research Collaboration, Exclusive License, and Option Agreement for Infectious Diseases with Vir Biotechnology

Combines Visterra’s Proprietary Hierotope® Platform Technology and Vir Biotechnology’s Expertise in Innovative Research & Development for Infectious Diseases Vir to License up to Five Infectious Disease Research Programs from Visterra; has Option to a Minority Interest in VIS410 Visterra Received Upfront Payment, to Receive Fundi...

Revint Solutions Formed to Lead Revenue Integrity in Healthcare Industry

More than 450 hospitals and healthcare delivery systems will benefit from Revint Solutions’ “safety net” to ensure accurate and timely reimbursement for services Eir Partners and BKO Capital are excited to announce the formation of Revint Solutions today with the vision of creating the country’s leading data-driven enterprise-wide solutions pro...

U.S. FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review

LYNPARZA Has the Potential to Offer a New Treatment Option for Patients with Germline BRCA-Mutated, HER2-Negative Metastatic Breast Cancer Regulatory Submission Acceptance Is the First for a PARP Inhibitor Beyond Ovarian Cancer AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the...

US FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review

LYNPARZA has the potential to offer a new treatment option for patients with germline BRCA-mutated, HER2-negative metastatic breast cancer Regulatory submission acceptance is first for a PARP inhibitor beyond ovarian cancer AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US...

FDA go-ahead shoots Diffusion shares up by a fifth

The regulatory agency says yes to the biotech's Phase 3 trial in inoperable brain cancer.

Van Leeuwenhoeck Issues Initiation of Coverage Research Report on Addex Therapeutics and Estimated ADXN Share Price of CHF 11.5 per Share

Addex Therapeutics / Van Leeuwenhoeck Issues Initiation of Coverage Research Report on Addex Therapeutics and Estimated ADXN Share Price of CHF 11.5 per Share . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Geneva, Switzerland, 18 October 2017 - Addex Therapeutics (SIX: ADXN) announced today that ...

Dassault Systèmes’ Living Heart Project Reaches Next Milestones in Mission to Improve Patient Care

Simulated digital 3D heart model now on the cloud offers new perspectives for medical research Project grows to 95 worldwide members, extends to simulating drug interactions with heart Supports FDA focus on simulation and modeling through the 21st

IntelliSoft Group Introduces New Hybrid Product that Combines Software and CVO Services at the National Association Medical Staff Services Annual Conference

IntelliSolution combines all the functionality of the credentialing, provider enrollment and contract management software along with the vast services offered by the CVO division, IntelliCVO. NASHUA, N.H. (PRWEB) October 18, 2017 IntelliSoft Group, LLC, a leading provider of healthcare credentialing, provider enrollment and contract management software products as well as credentials verification...

Tuesday 17th October 2017

Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan

Poziotinib demonstrates evidence of significant antitumor activity in NSCLC patients with EGFR exon 20 insertion mutations, with interim data showing an Objective Response Rate of 73%. Evidence of central nervous system (CNS) activity in a patient with CNS metastasis and another with leptomeningeal disease (LMD). ...

Cerecor, Inc. Regains Compliance with NASDAQ Minimum Bid Price Requirement

BALTIMORE, MD--(Marketwired - October 18, 2017) - Cerecor, Inc. (NASDAQ: CERC), a biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that it received a letter from the Nasdaq Listing Qualifications Staff (the "Staff") confirming that it has regained compliance with the minimum bid price requirement under Nas...

Critical Outcome Technologies Closes Second Tranche of $2 Million Private Placement

LONDON, ONTARIO and BOSTON, MASSACHUSETTS -- (Marketwired) -- 10/18/17 -- Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced the closing of the second tranche of a $2 million non-brokered private placement announced Septemb...

Spectral Announces Retirement of Chief Financial Officer

TORONTO, ONTARIO -- (Marketwired) -- 10/18/17 -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT) a Phase III Company advancing a precision treatment targeting specific patients at high risk of death from endotoxemic septic shock, today announced that Tony Businskas will be retiring as the Executive Vice President and CFO of the Company on January 31, 2018, after 12 years of servic...

CTD Holdings Closes $1.5 Million Private Placement

ALACHUA, FL--(Marketwired - October 18, 2017) - CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that it has closed a private placement of its securities with a group of accredited investors that included several directors of the Company and members of management...

RenovaCare, Inc. Closes Registered Direct Offering and Concurrent Private Placement

RenovaCare, Inc., (OTCQB:RCAR), developer of the SkinGun™ and CellMist™ System for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today announced that it has entered into definitive agreements with investors to purchase an aggregate of approximately 915,000 shares of common stock in a registered direct ...

Rubicon Research Pvt Ltd Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14092017] Prices from USD $250

SummaryRubicon Research Pvt Ltd Rubicon, a subsidiary of Everstone Capital Management, is a contract research and a drug delivery technology company that develops, manufactures and markets nextgeneration products. The company's products include central nervous system, cardiovascular, cough, cold and anti allergy, analgesics, metabolics and nutritional dietary supplements. It offers products in var...


Quick Search
Advertisement
 

News Quicklinks